Hot Features
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and he... Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.075 | -9.31677018634 | 0.805 | 0.83 | 0.73 | 236793 | 0.78128786 | CS |
| 4 | -0.1397 | -16.0630102334 | 0.8697 | 0.9 | 0.65 | 441277 | 0.74939674 | CS |
| 12 | -0.121 | -14.2185663925 | 0.851 | 1.23 | 0.65 | 1385903 | 0.94833681 | CS |
| 26 | 0.1 | 15.873015873 | 0.63 | 1.23 | 0.475 | 2944122 | 0.88130798 | CS |
| 52 | -0.49 | -40.1639344262 | 1.22 | 1.8 | 0.475 | 1810991 | 0.89795416 | CS |
| 156 | -2.52 | -77.5384615385 | 3.25 | 6.39 | 0.3313 | 1830924 | 2.20491413 | CS |
| 260 | -6.04 | -89.2171344165 | 6.77 | 45 | 0.3313 | 2047014 | 8.63438822 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.